Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2023-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Nonepileptic Seizures, Functional Movement Disorders and Functional Weakness. Clinical research across these motor FND subtypes, including research studies from the candidate's laboratory, suggest that these populations share many clinical and phenotypic similarities that warrant increased research integration. Furthermore, despite the prevalence of motor FND, little is known about the underlying pathophysiology of this condition, which is a prerequisite for the development of biologically informed prognostic and treatment response biomarkers. Across 3 published neurobiologically focused articles, the candidate proposed a framework through which to conceptualize motor FND. It is suggested that motor FND develops in the context of structural and functional alterations in neurocircuits mediating emotion awareness/expression, bodily awareness, viscerosomatic processing and behavioral regulation. The overall goal of this project is to comprehensively investigate structural and functional magnetic resonance imaging (MRI) biomarkers of prognosis across motor FND. Multimodal structural and functional MRI techniques (including voxel-based morphometry, cortical thickness, resting-state functional connectivity and diffusion tensor imaging tractography) will be used to systemically probe brain-prognosis relationships. Novel aspects of this proposal include the study of the full spectrum of motor FND, consistent with a trans-diagnostic approach.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder

NCT05305014

Conversion Disorder

COMPLETED

Studying Motor Neuron Tests

NCT01517087

Healthy Subjects Magnetic Resonance Imaging Central Nervous System +2 more

COMPLETED

Brain Activity in People With Functional Movement Disorders

NCT00448084

Functional Movement Disorders

COMPLETED

Brain Network Characteristics in Patients With Disorders of Consciousness

NCT05558670

Disorders of Consciousness

UNKNOWN

Prognostication of Recovery in Early Disorders of Consciousness Study

NCT04692922

Disorders of Consciousness Due to Severe Brain Injury

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Functional Neurological Disorder (FND) (Conversion Disorder) is a poorly understood and prevalent somatoform disorder, making up 16% of outpatient neurology referrals. Patients with motor FND (mFND) are difficult to treat, result in major morbidity, and are costly to the US. An estimated $256 billion is spent annually treating this population. mFND includes Nonepileptic Seizures (NES), Functional Movement Disorders (FMD) and Functional Weakness (FW). An impediment to managing mFND is the lack of a neurobiological understanding for this disorder. The diagnosis of mFND is currently based on qualitative aspects of behaviors, which may be difficult to interpret, and the absence of findings characteristic of other neuropsychiatric disorders on laboratory studies such as electroencephalography (EEG) and magnetic resonance imaging (MRI).

A major step forward would be the identification of neuroimaging biomarkers for mFND. mFND is understudied compared to other disorders, but recent studies point to distributed neurocircuit alterations associated with mFND. This project aims to advance our biological understanding of mFND by investigating neuroimaging biomarkers linked to prognosis. An improved understanding of the pathophysiology of mFND will provide a critical step in elucidating diagnostic, prognostic and treatment response biomarkers.

Aim:

Identify structural and functional biomarkers of prognosis at 6-months in patients with motor functional neurological disorders receiving an updated standard of care.

H1: Favorable mFND prognosis at 6 months post initial evaluation will be predicted by the degree of preserved baseline gray matter in limbic-paralimbic regions, particularly those part of the salience network.

H2: Favorable mFND prognosis at 6 months post initial evaluation will be predicted by the degree of preserved baseline resting-state functional connectivity in limbic/paralimbic areas, particularly those part of the salience network.

H3: Favorable mFND prognosis at 6 months will correlate with the degree of preserved baseline cingulum bundle and cingulum-insular tract integrity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Conversion Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Motor Functional Neurological Disorder.

The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.

Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.

The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:

1. Delivery of a positive "rule-in" diagnosis of functional neurological disorder
2. Individuals are provided with educational materials on functional neurological disorders
3. Referred to physical therapy and/or occupational therapy as clinically indicated
4. FND related cognitive behavioral therapy (CBT) referral when appropriate
5. Psychotropic medication management based on standard psychiatric care

Standard of Care

Intervention Type OTHER

The standard of care interventions for Functional Neurological Disorders (FND) include:

1. delivery of a rule-in diagnosis
2. providing educational materials
3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated
4. referring to FND-related cognitive behavioral therapy (CBT)
5. psychotropic medication management based on standard psychiatric care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care

The standard of care interventions for Functional Neurological Disorders (FND) include:

1. delivery of a rule-in diagnosis
2. providing educational materials
3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated
4. referring to FND-related cognitive behavioral therapy (CBT)
5. psychotropic medication management based on standard psychiatric care

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinically established motor functional neurological disorder, including individuals with functional movement disorders, functional limb weakness and psychogenic nonepileptic seizures

Exclusion Criteria

* active suicidality
* major medical/neurological comorbidities with known central nervous system (CNS) consequences
* active drug use or alcohol dependence
* known history of a primary psychotic disorder

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No